Lilly’s bamlanivimab plus etesevimab cut death, hospitalisations for early COVID-19 in Phase… EP News Bureau Mar 11, 2021 Results support use of bamlanivimab 700 mg and etesevimab 1400 mg, the dose authorised in the US and several other countries
AbCellera gets EUA from US FDA for its antibody Bamlanivimab, along with Etesevimab for COVID-19 EP News Bureau Feb 10, 2021 Lilly plans to manufacture more than 250,000 doses of the bamlanivimab and etesevimab therapy throughout Q1 2021, and up to a…
